Cited by 58Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancerNatural Antidiabetic Agents Studies

Insulin signalling downstream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo

Open access
Longnus, S. L., Ségalen, C., Giudicelli, J., Sajan, M. P., Farese, R. V., Van Obberghen, E.·2005·Diabetologia

Abstract

Aims/hypothesis 5'AMP-activated protein kinase (AMPK) and insulin stimulate glucose transport in heart and muscle. AMPK acts in an additive manner with insulin to increase glucose uptake, thereby suggesting that AMPK activation may be a useful strategy for ameliorating glucose uptake, especially in cases of insulin resistance. In order to characterise interactions between the insulin- and AMPK-signalling pathways, we investigated the effects of AMPK activation on insulin signalling in the rat heart in vivo.Methods Male rats (350-400 g) were injected with 1 g/kg 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) or 250 mg/kg metformin in order to activate AMPK. Rats were administered insulin 30 min later and after another 30 min their hearts were removed. The activities and phosphorylation levels of components of the insulin-signalling pathway were subsequently analysed in individual rat hearts.Results AICAR and metformin administration activated AMPK and enhanced insulin signalling downstream of protein kinase B in rat hearts in vivo. Insulin-induced phosphorylation of glycogen synthase kinase 3 (GSK3) beta, p70 S6 kinase (p70S6K)(Thr389) and IRS1(Ser636/639) were significantly increased following AMPK activation. To the best of our knowledge, this is the first report of heightened insulin responses of GSK3beta and p70S6K following AMPK activation. In addition, we found that AMPK inhibits insulin stimulation of IRS1-associated phosphatidylinositol 3-kinase activity, and that AMPK activates atypical protein kinase C and extracellular signal-regulated kinase in the heart.Conclusions/interpretations Our data are indicative of differential effects of AMPK on the activation of components in the cardiac insulin-signalling pathway. These intriguing observations are critical for characterisation of the crosstalk between AMPK and insulin signalling.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-005-0016-3

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AMPK regulates IRS-1 and Akt/PKB, whereas insulin and Akt have negative impacts on AMPK activation in adipocytes.

    “It has been reported that AMPK regulates IRS-1 and Akt/PKB (23), whereas insulin and Akt have negative impacts on AMPK activation in adipocytes (6).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Longnus, S. L., Ségalen, C., Giudicelli, J., Sajan, M. P., Farese, R. V., & Van Obberghen, E.
Affiliations
  • Inserm (FR)
  • University of South Florida (US)
Venue
Diabetologia
Published
2005-11-11
Volume
48
Issue
12
Pages
2591-2601
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W1986364902
Cited by
58
References
83
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 7
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065969, R01-DK065969-01A1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
AMPK, insulin signaling, Akt, glycogen synthase kinase-3β, p70 S6 kinase, IRS-1, phosphatidylinositol 3-kinase, atypical protein kinase C, extracellular signal-regulated kinase, glucose uptake, AICAR, metformin, insulin resistance
MeSH terms
Glycogen Synthase Kinase 3 beta, Aminoimidazole Carboxamide, Animals, Blood Glucose, Enzyme Activation, Heart, Insulin, Male, Metformin, Multienzyme Complexes, Myocardium, Phosphoproteins, Phosphorylation, Protein Kinase C, Ribonucleotides, Signal Transduction, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Phosphatidylinositol 3-Kinases, Glycogen Synthase Kinase 3, Ribosomal Protein S6 Kinases, 70-kDa, Mitogen-Activated Protein Kinase 3, Proto-Oncogene Proteins c-akt, Rats, AMP-Activated Protein Kinases, Insulin Receptor Substrate Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review